Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Innovation Pharmaceuticals IPIX
Posted On: 03/01/2013 6:11:06 PM
Post# of 72446
Avatar
Posted By: seel

Some areas the doc at SK has an interest in and has actively researched...The third one is, in my opinion, probably the one ctix is interested in. But of course I'm not sure.


Total Synthesis of Garsubellin A


potential as a therapeutic agent for the treatment of Alzheimer's disease


http://pubs.acs.org/doi/abs/10.1021/ja057418n


_______________________________________________________________________


Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones


Although these compounds operate through a microtubule stabilization mechanism similar to that of taxol, the epothilones offer a major potential therapeutic advantage in that they retain their activity against multidrug-resistant cell lines.


http://www.pnas.org/content/105/35/13157.short


________________________________________________________________________


If I had to place a bet, based on just this quick scan of his prolific volume of work (this guy is a true supergenius) - my bet would be that what ctix just purchased is related to this research. The doc has spent much time in this specific subject matter.


Probing the stability of nonglycosylated wild-type erythropoietin protein via reiterative alanine ligations



Erythropoietin (EPO) is a glycoprotein hormone that is responsible for the regulation and maintenance of erythrocytes ( 1 ). Binding of EPO, which is produced in the kidney, to the EPO receptor (EPO-R) located in the bone marrow, stimulates the production of erythrocytes by the process of erythropoiesis. EPO derived from recombinant methods is used for the treatment of anemia associated with renal failure, cancer, and chemotherapy ( 2 ). Production of recombinant EPO, using genetically modified Chinese hamster ovary (CHO) cells, results in a heterogeneous mixture of glycoforms —molecules that differ with respect to glycan structure.


http://www.pnas.org/content/109/19/7196.short














(0)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site